Treatment with mouse anti-IL-22 nAb resulted in a reduction in the HW/BW and LW/TL ratios and the CSA in angiotensin II-induced cardiac hypertrophy mice (Figure 2(b)). This evidence concerns the gene IL22 and cardiac hypertrophy.